TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Rodrigues Díez, Raquel ^a   Rayego Mateos, Sandra ^a   Orejudo, Macarena ^a   Aroeira, Luiz Stark ^b   Selgas, Rafael ^c   Ortiz, Alberto ^d   Egido, Jesús ^d   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^d UAM)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; CHEMOKINE RECEPTOR CCR2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; EVALUATION STUDY; FIBROGENESIS; GENE EXPRESSION; KIDNEY CELL; KIDNEY INJURY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; KIDNEY; METABOLISM;

MUS;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CCR2; TRANSFORMING GROWTH FACTOR BETA;

EID: 84929648965     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/506041     Document Type: Article

References (73)

1. K. Matsushita, M. van der Velde, B. C. Astor et al., "Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis," The Lancet, vol. 375, no. 9731, pp. 2073-2081, 2010.
2. P. de Winter, P. Leoni, and D. Abraham, "Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein," Growth Factors, vol. 26, no. 2, pp. 80-91, 2008.
3. D. M. Bradham, A. Igarashi, R. L. Potter, and G. R. Grotendorst, "Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10," Journal of Cell Biology, vol. 114, no. 6, pp. 1285-1294, 1991.
4. D. R. Brigstock, R. Goldschmeding, K.-I. Katsube et al., "Proposal for a unified CCN nomenclature," The Journal of Clinical Pathology - Molecular Pathology, vol. 56, no. 2, pp. 127-128, 2003.
5. F. W. K. Tam, B. L. Riser, K. Meeran, J. Rambow, C. D. Pusey, and A. H. Frankel, "Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy,"Cytokine, vol. 47, no. 1, pp. 37-42, 2009.
6. T. Q. Nguyen, L. Tarnow, S. Andersen et al., "Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy," Diabetes Care, vol. 29, no. 1, pp. 83-88, 2006.
7. R. E. Gilbert, A. Akdeniz, S. Weitz et al., "Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy," Diabetes Care, vol. 26, no. 9, pp. 2632-2636, 2003.
8. N. Koitabashi, M. Arai, K. Niwano et al., "Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure," European Journal of Heart Failure, vol. 10, no. 4, pp. 373-379, 2008.
9. K. Frazier, S. Williams, D. Kothapalli, H. Klapper, and G. R. Grotendorst, "Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor," Journal of Investigative Dermatology, vol. 107, no. 3, pp. 404-411, 1996.
10. A. Leask, "CCN2: a novel, specific and valid target for antifibrotic drug intervention," Expert Opinion on Therapeutic Targets, vol. 17, no. 9, pp. 1067-1071, 2013.
11. M. Ruiz-Ortega, J. Rodríguez-Vita, E. Sanchez-Lopez, G. Carvajal, and J. Egido, "TGF-β signaling in vascular fibrosis,"Cardiovascular Research, vol. 74, no. 2, pp. 196-206, 2007.
12. H. Yokoi, M. Mukoyama, T. Nagae et al., "Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis," Journal of the American Society of Nephrology, vol. 15, no. 6, pp. 1430-1440, 2004.
13. H. Okada, T. Kikuta, T. Kobayashi et al., "Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis," Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 133-143, 2005.
14. M. Guha, Z.-G. Xu, D. Tung, L. Lanting, and R. Natarajan, "Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes," The FASEB Journal, vol. 21, no. 12, pp. 3355-3368, 2007.
15. C.-C. Chen and L. F. Lau, "Functions and mechanisms of action of CCN matricellular proteins," International Journal of Biochemistry and Cell Biology, vol. 41, no. 4, pp. 771-783, 2009.
16. S. Rayego-Mateos, R. Rodrigues-Díez, J. L. Morgado-Pascual et al., "Connective tissue growth factor is a new ligand of epidermal growth factor receptor," Journal of Molecular Cell Biology, vol. 5, no. 5, pp. 323-335, 2013.
17. B.-C. Liu, J.-D. Zhang, X.-L. Zhang, G.-Q. Wu, and M.-X. Li, "Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition (EMT) in HK-2 cells," Clinica Chimica Acta, vol. 373, no. 1-2, pp. 144-150, 2006.
18. L. Kular, J. Pakradouni, P. Kitabgi, M. Laurent, and C. Mar "The CCN family: a new class of inflammation modulators?"Biochimie, vol. 93, no. 3, pp. 377-388, 2011.
19. I. Cicha, A. Yilmaz, M. Klein et al., "Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 5, pp. 1008-1013, 2005.
20. R. Rodrigues-Díez, R. R. Rodrigues-Díez, S. Rayego-Mateos et al., "The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response,"Laboratory Investigation, vol. 93, no. 7, pp. 812-824, 2013.
21. E. Sánchez-López, S. Rayego, R. Rodrigues-Díez et al., "CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-κB," Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1513-1526, 2009.
22. T. Mori, S. Kawara, M. Shinozaki et al., "Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model," Journal of Cellular Physiology, vol. 181, no. 1, pp. 153-159, 1999.
23. J. Das, G. Ren, L. Zhang et al., "Transforming growth factor β is dispensable for the molecular orchestration of Th17 cell differentiation," The Journal of Experimental Medicine, vol. 206, no. 11, pp. 2407-2416, 2009.
24. P. Devarajan, "Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease," Scandinavian Journal of Clinical & Laboratory Investigation, vol. 68, no. s241, pp. 89-94, 2008.
25. J. A. Moreno, S. Moreno, A. Rubio-Navarro et al., "Targeting chemokines in proteinuria-induced renal disease," Expert Opinion on Therapeutic Targets, vol. 16, no. 8, pp. 833-845, 2012.
26. S. Hori, T. Nomura, and S. Sakaguchi," Control of regulatory T cell development by the transcription factor Foxp3," Science, vol. 299, no. 5609, pp. 1057-1061, 2003.
27. M. R. Walker, D. J. Kasprowicz, V. H. Gersuk et al., "Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+ CD25- T cells," The Journal of Clinical Investigation, vol. 112, no. 9, pp. 1437-1443, 2003.
28. M. Takigawa, "CCN2: a master regulator of the genesis of bone and cartilage," Journal of Cell Communication and Signaling, vol. 7, no. 3, pp. 191-201, 2013.
29. E. Aoyama, T. Hattori, M. Hoshijima et al., "N-terminal domains of CCN family 2/connective tissue growth factor bind to aggrecan," Biochemical Journal, vol. 420, no. 3, pp. 413-420, 2009.
30. J. G. Abreu, N. I. Ketpura, B. Reversade, and E. M. De Robertis, "Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β," Nature Cell Biology, vol. 4, no. 8, pp. 599-604, 2002.
31. H. C. O'Donovan, F. Hickey, D. P. Brazil et al., "Connective tissue growth factor antagonizes transforming growth factor-β1/Smad signalling in renal mesangial cells," Biochemical Journal, vol. 441, no. 1, pp. 499-510, 2012.
32. G. R. Grotendorst and M. R. Duncan, "Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation," The FASEB Journal, vol. 19, no. 7, pp. 729-738, 2005.
33. R. R. Rodrigues-Diez, A. B. Garcia-Redondo, M. Orejudo et al., "The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells,"Antioxidants & Redox Signaling, vol. 22, no. 1, pp. 29-47, 2015.
34. M. Rupérez, M. Ruiz-Ortega, V. Esteban et al., "Angiotensin II increases connective tissue growth factor in the kidney," The American Journal of Pathology, vol. 163, no. 5, pp. 1937-1947, 2003.
35. G. Carvajal, J. Rodríguez-Vita, R. Rodrigues-Díez et al., "Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation," Kidney International, vol. 74, no. 5, pp. 585-595, 2008.
36. E. Sánchez-López, R. R. Díez, J. R. Vita et al., "Connective tissue growth factor (CTGF): a key factor in the onset and progression of kidney damage," Nefrologia, vol. 29, no. 5, pp. 382-391, 2009.
37. Y. Shi and J. Massagué, "Mechanisms of TGF-β signaling from cell membrane to the nucleus," Cell, vol. 113, no. 6, pp. 685-700, 2003.
38. J. B. Kopp, V. M. Factor, M. Mozes et al., "Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease," Laboratory Investigation, vol. 74, no. 6, pp. 991-1003, 1996.
39. J. Loureiro, A. Aguilera, R. Selgas et al., "Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage," Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1682-1695, 2011.
40. E. P. Bottinger, "TGF-beta in renal injury and disease," Seminars in Nephrology, vol. 27, pp. 309-320, 2007.
41. W. Wang, X. R. Huang, A. G. Li et al., "Signaling mechanism of TGF-β1 in prevention of renal inflammation: role of Smad7,"Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1371-1383, 2005.
42. W. Wang, V. Koka, and H. Y. Lan, "Transforming growth factor-β and Smad signalling in kidney diseases," Nephrology, vol. 10, no. 1, pp. 48-56, 2005.
43. A. A. Eddy and E. G. Neilson, "Chronic kidney disease progression,"Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 2964-2966, 2006.
44. T. Yamamoto, N. A. Noble, A. H. Cohen et al., "Expression of transforming growth factor-β isoforms in human glomerular diseases," Kidney International, vol. 49, no. 2, pp. 461-469, 1996.
45. T. M. Coimbra, J. Carvalho, A. Fattori, C. G. A. Da Silva, and J. J. Lachat, "Transforming growth factor-β production during the development of renal fibrosis in rats with subtotal renal ablation," International Journal of Experimental Pathology, vol. 77, no. 4, pp. 167-173, 1996.
46. R. E. Gilbert, A. Cox, L. L. Wu et al., "Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition," Diabetes, vol. 47, no. 3, pp. 414-422, 1998.
47. C. Hill, A. Flyvbjerg, H. Grønbæk et al., "The renal expression of transforming growth factor-β isoforms and their receptors in acute and chronic experimental diabetes in rats," Endocrinology, vol. 141, no. 3, pp. 1196-1208, 2000.
48. S. J. Shankland, J. Pippin, R. H. Pichler et al., "Differential expression of transforming growth factor β-isoforms and receptors in experimental membranous nephropathy," Kidney International, vol. 50, no. 1, pp. 116-124, 1996.
49. I. S. Park, H. Kiyomoto, S. L. Abboud, and H. E. Abboud, "Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes," Diabetes, vol. 46, no. 3, pp. 473-480, 1997.
50. W. A. Border and N. A. Noble, "TGF-β in kidney fibrosis: a target for gene therapy," Kidney International, vol. 51, no. 5, pp. 1388-1396, 1997.
51. K. Sharma, Y. Jin, J. Guo, and F. N. Ziyadeh, "Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice," Diabetes, vol. 45, no. 4, pp. 522-530, 1996.
52. F. N. Ziyadeh, B. B. Hoffman, D. C. Han et al., "Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 8015-8020, 2000.
53. L.-J. Ma, S. Jha, H. Ling, A. Pozzi, S. Ledbetter, and A. B. Fogo, "Divergent effects of low versus high dose anti-TGF-β antibody in puromycin aminonucleoside nephropathy in rats," Kidney International, vol. 65, no. 1, pp. 106-115, 2004.
54. X.-M. Meng, X. R. Huang, J. Xiao et al., "Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro," Journal of Pathology, vol. 227, no. 2, pp. 175-188, 2012.
55. A. B. Kulkarni, C.-G. Huh, D. Becker et al., "Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 770-774, 1993.
56. J. C. Marie, D. Liggitt, and A. Y. Rudensky, "Cellular mecha of fatal early-onset autoimmunity in mice with the T cellspecific targeting of transforming growth factor-β receptor,"Immunity, vol. 25, no. 3, pp. 441-454, 2006.
57. M. O. Li, S. Sanjabi, and R. Flavell, "Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms," Immunity, vol. 25, no. 3, pp. 455-471, 2006.
58. W. Chen, W. Jin, M. Cook, H. L. Weiner, and S. M. Wahl, "Oral delivery of group A streptococcal cell walls augments circulating TGF-β and suppresses streptococcal cell wall arthritis,"Journal of Immunology, vol. 161, no. 11, pp. 6297-6304, 1998.
59. Y. X. Jin, L. Y. Xu, H. Guo, M. Ishikawa, H. Link, and B.-G. Xiao, "TGF-beta1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells,"Journal of Autoimmunity, vol. 14, no. 3, pp. 213-220, 2000.
60. C. A. Piccirillo, Y. Chang, and G. J. Prud'homme, "TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice," Journal of Immunology, vol. 161, no. 8, pp. 3950-3956, 1998.
61. X. R. Huang, A. C. K. Chung, X. J. Wang, K. N. Lai, and H. Y. Lan, "Mice overexpressing latent TGF-β1 areprotected against renal fibrosis in obstructive kidney disease," American Journal of Physiology - Renal Physiology, vol. 295, no. 1, pp. F118-F127, 2008.
62. I.-M. Chung, J. Kim, Y. K. Pak et al., "Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries," International Journal of Cardiology, vol. 145, no. 3, pp. 468-475, 2010.
63. Z. Mallat, A. Gojova, C. Marchiol-Fournigault et al., "Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice," Circulation Research, vol. 89, no. 10, pp. 930-934, 2001.
64. E. Lutgens, M. Gijbels, M. Smook et al., "Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 6, pp. 975-982, 2002.
65. A.-K. L. Robertson, M. Rudling, X. Zhou, L. Gorelik, R. A. Flavell, and G. K. Hansson, "Disruption of TGF-β signaling in T cells accelerates atherosclerosis," The Journal of Clinical Investigation, vol. 112, no. 9, pp. 1342-1350, 2003.
66. W. Chen, W. Jin, N. Hardegen et al., "Conversion of Peripheral CD4+ CD25- Naive T Cells to CD4+ CD25+ Regulatory T Cells by TGF-beta Induction of Transcription Factor Foxp3," The Journal of Experimental Medicine, vol. 198, no. 12, pp. 1875-1886, 2003.
67. S. G. Zheng, J. D. Gray, K. Ohtsuka, S. Yamagiwa, and D. A. Horwitz, "Generation ex vivo of TGF-beta producing regulatory T cells from CD4+CD25- precursors," The Journal of Immunology, vol. 169, no. 8, pp. 4183-4189, 2002.
68. J. B. Wing and S. Sakaguchi, "Foxp3+ Treg cells in humoral immunity," International Immunology, vol. 26, no. 2, pp. 61-69, 2014.
69. T. Barhoumi, D. A. Kasal, M. W. Li et al., "T Regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury," Hypertension, vol. 57, no. 3, pp. 469-476, 2011.
70. D. Mahajan, Y. Wang, X. Qin et al., "CD4+ CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease," Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 2731-2741, 2006.
71. D. Wolf, K. Hochegger, A. M. Wolf et al., "CD4+ CD25+regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice," Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1360-1370, 2005.
72. Q. Xing, H. Su, J. Cui, and B. Wang, "Role of treg cells and TGF-β1 in patients with systemic lupus erythematosus: a possible relation with lupus nephritis," Immunological Investigations, vol. 41, no. 1, pp. 15-27, 2012.
73. Q. Xing, B. Wang, H. Su, J. Cui, and J. Li, "Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis," Rheumatology International, vol. 32, no. 4, pp. 949-958, 2012.